Sanofi/Regeneron Ready To Forge Ahead With Libtayo Filings In NSCLC
Cemiplimab was a latecomer to the PD-1/L1 class, but a Phase III success in lung cancer will bring it to the main stage for immuno-oncology.
Cemiplimab was a latecomer to the PD-1/L1 class, but a Phase III success in lung cancer will bring it to the main stage for immuno-oncology.